Article Text

Download PDFPDF

LP-197 Association between steroid therapy and IGRA Result in systemic lupus erythematosus
  1. Naurah Alzena Hana Dhea1,
  2. Guntur Darmawan2,3,
  3. Alya Dharmaninda3,
  4. Edhyana Sahiratmadja1,4 and
  5. Laniyati Hamijoyo1,5
  1. 1Lupus Study Group, Study Center of Immunology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
  2. 2Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
  3. 3Department of Internal Medicine, Faculty of Medicine, Krida Wacana Christian University, Jakarta, Indonesia
  4. 4Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
  5. 5Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung, Indonesia


Background Systemic Lupus Erythematosus (SLE) is an autoimmune disease caused by disturbance in immune tolerance to self-antigens, leading to multiorgan inflammation. SLE causes a high risk of tuberculosis (TB) infection in SLE. In SLE pathogenesis, T cells play a major role to amplify inflammation by secreting pro-inflammatory cytokines. Interferon-γ release assay (IGRA) is commonly used to diagnose latent TB infection (LTBI). Many immunosuppressive agents are potent inhibitors of T cells and may impair the interferon-γ response. This study was aimed to determine the effect of steroid therapy on the performance of IGRA in SLE.

Methods This experimental study included 50 female SLE. Data such as age, disease duration, SLE disease activity index (SLEDAI), steroid therapy doses, and Body Mass Index (BMI) were obtained. Steroid therapy doses were categorized as high-dose (≥7.50 mg) and low-dose steroids (<7.50 mg). Patients were excluded if they had history of TB or current active TB. Each group underwent IGRA testing using the QuantiFERON-TB Gold Plus kit. Data analysis was performed using SPSS.

Results There were 50 (100%) female SLE with average age 32.64 (±8.16) years old, mean disease duration 5.78 (±3.99) years, mean SLEDAI score 2.64 (±3.19), mean steroid therapy doses 8.47 (±8.35) mg/day, and median of BMI 21.7 (16.4–36.0). In high-dose steroids group (n=20), IGRA result was 5% positive, 15% indeterminate, and 80% negative. In low-dose steroids group, 3.3% was positive and 96.7% was negative. There was no significant association between steroid therapies and IGRA results (p=0.084).

Conclusions Steroid therapy causes dysregulation of immune response and has tendency to influence IGRA result in SLE. In our study steroid therapy is not associated with IGRA result. Further study to explore latent tuberculosis infection and steroid therapy in SLE is of great interest.

  • systemic lupus erythematosus
  • steroid
  • IGRA

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.